Alliqua BioMedical, Inc. (ALQA)

FORM 8-K | Current report
Dec. 8, 2017 5:00 PM
About: Alliqua BioMedical, Inc. (ALQA)View as PDF
Alliqua BioMedical, Inc. (Form: 8-K, Received: 12/08/2017 17:01:47)











Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934




Date of Report (Date of earliest event reported): December 5, 2017


Alliqua BioMedical, Inc.


(Exact Name of Registrant as Specified in its Charter)


Delaware   001-36278   58-2349413
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)


1010 Stony Hill Road

Suite 200

Yardley, Pennsylvania

(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: (215) 702-8550


Former name or former address, if changed since last report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officer.


On December 5, 2017, Jerome Zeldis M.D., Ph.D., resigned from the board of directors of Alliqua BioMedical, Inc. (the “Company”), effective immediately. Dr. Zeldis’ decision to resign from the Board did not result from any disagreement with the Company or its management.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: December 8, 2017 By: /s/ Brian Posner
    Name: Brian Posner
    Title:   Chief Financial Officer